XIAP Monoclonal Antibody

$Lane 1: Human MCF-7 cell lysates; Lane 2: Human MOLT4 cell lysates; Lane 3: Human HeLa cell lysates; Lane 4: Human Raji cell lysates; Lane 5: Human Jurkat cell lysates; Lane 6: Human HepG2 cell lysates; Lane 7: Human A549 cell lysates probed with XIAP Monoclonal Antibody, Unconjugated (bsm-51607M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human MCF-7 cell lysates; Lane 2: Human MOLT4 cell lysates; Lane 3: Human HeLa cell lysates; Lane 4: Human Raji cell lysates; Lane 5: Human Jurkat cell lysates; Lane 6: Human HepG2 cell lysates; Lane 7: Human A549 cell lysates probed with XIAP Monoclonal Antibody, Unconjugated (bsm-51607M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
IHC-P
IHC-F
IF

Reactivity

Human

Overview
Catalog #	bsm-51607m
Product Name	XIAP Monoclonal Antibody
Applications	WB, IHC-P, IHC-F, IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant human XIAP.
Clonality	Monoclonal
Clone #	D1G6
Isotype	IgG1 κ
Concentration	0.5ug/ul
Purification	Purified by Protein G.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	331
Swiss Prot	P98170
Subcellular location	Cytoplasm
Synonyms	X-linked Inhibitor of Apoptosis Protein; RIAP-3; Baculoviral IAP repeat-containing protein 4; E3 ubiquitin-protein ligase XIAP; Inhibitor of apoptosis protein 3; X-linked IAP; IAP-like protein; HILP; BIRC4; HILP; XLP2; ILP1; Xiap; MIHA; hILP; IAP3; API3; XIAP_HUMAN; ILP; hILP; IAP-3; hIAP-3; hIAP3; X-linked inhibitor of apoptosis protein.
Background	Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Application Dilution
WB	1:500-4000
IHC-P	IHC-P1:20-100
IHC-F	IHC-F1:20-100
IF	IF1:20-100